<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet href="https://rss.buzzsprout.com/styles.xsl" type="text/xsl"?>
<rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:podcast="https://podcastindex.org/namespace/1.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:psc="http://podlove.org/simple-chapters" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <atom:link href="https://rss.buzzsprout.com/2518667.rss" rel="self" type="application/rss+xml" />
  <atom:link href="https://pubsubhubbub.appspot.com/" rel="hub" xmlns="http://www.w3.org/2005/Atom" />
  <title>Better Biopharma</title>

  <lastBuildDate>Wed, 20 May 2026 00:05:17 -0400</lastBuildDate>
  <link>https://www.buzzsprout.com/2518667</link>
  <language>en</language>
  <copyright>© 2026 Better Biopharma</copyright>
  <podcast:locked>yes</podcast:locked>
    <podcast:guid>fc20d31a-9520-5445-b6a5-d4de2eea1486</podcast:guid>
  <itunes:author>Tyler Menichiello</itunes:author>
  <itunes:type>episodic</itunes:type>
  <itunes:explicit>false</itunes:explicit>
  <description><![CDATA[<p>“How can biopharma improve?” This question is the guiding ethos of the <em>Better Biopharma</em> podcast. Through conversations with experts across the biopharma landscape, host Tyler Menichiello explores the work being done to make better medicines and optimize manufacturing. Each episode is a dive into the guest's methods, their curiosity, and their determination. By shining a light on the visionaries pushing the industry forward, <em>Better Biopharma </em>aims to inform and inspire their peers to continue doing the same.</p><p><br><br></p>]]></description>
  <generator>Buzzsprout (https://www.buzzsprout.com)</generator>
  <itunes:owner>
    <itunes:name>Tyler Menichiello</itunes:name>
  </itunes:owner>
  <image>
     <url>https://storage.buzzsprout.com/ths7kek12vdb45uw9j039a1sw1i2?.jpg</url>
     <title>Better Biopharma</title>
     <link></link>
  </image>
  <itunes:image href="https://storage.buzzsprout.com/ths7kek12vdb45uw9j039a1sw1i2?.jpg" />
  <itunes:category text="Science">
    <itunes:category text="Life Sciences" />
  </itunes:category>
  <item>
    <itunes:title>Validation Challenges Facing Advanced Single-Use Technologies</itunes:title>
    <title>Validation Challenges Facing Advanced Single-Use Technologies</title>
    <itunes:summary><![CDATA[In this episode of "Better Biopharma," host Tyler Menichiello is joined by BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a consultant and single-use expert, to continue their conversation from the Bioprocess Online Live event, "Closing The Adoption Gap For Advanced Single-Use Materials." Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonli...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a consultant and single-use expert, to continue their conversation from the <em>Bioprocess Online Live</em> event, &quot;<a href='https://www.bioprocessonline.com/doc/closing-the-adoption-gap-for-advanced-single-use-materials-0001'>Closing The Adoption Gap For Advanced Single-Use Materials</a>.&quot;</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by BioPlan Associates’ director of research, Katrina Cordovado, as well as Joshua Nelson, Ph.D., a senior material qualification specialist at Takeda, and Paul Priebe, a consultant and single-use expert, to continue their conversation from the <em>Bioprocess Online Live</em> event, &quot;<a href='https://www.bioprocessonline.com/doc/closing-the-adoption-gap-for-advanced-single-use-materials-0001'>Closing The Adoption Gap For Advanced Single-Use Materials</a>.&quot;</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/19196256-validation-challenges-facing-advanced-single-use-technologies.mp3" length="50617546" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-19196256</guid>
    <pubDate>Wed, 20 May 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19196256/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19196256/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19196256/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19196256/transcript.vtt" type="text/vtt" />
    <itunes:duration>4180</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Aligning Upstream And Downstream Development (Part 2)</itunes:title>
    <title>Aligning Upstream And Downstream Development (Part 2)</title>
    <itunes:summary><![CDATA[In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https:/...]]></itunes:summary>
    <description><![CDATA[<p>In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “<a href='https://www.bioprocessonline.com/doc/optimizing-process-development-through-upstream-and-downstream-integration-0001'>Optimizing Process Development Through Upstream And Downstream Integration</a>” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “<a href='https://www.bioprocessonline.com/doc/optimizing-process-development-through-upstream-and-downstream-integration-0001'>Optimizing Process Development Through Upstream And Downstream Integration</a>” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/19122846-aligning-upstream-and-downstream-development-part-2.mp3" length="12566172" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-19122846</guid>
    <pubDate>Wed, 06 May 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19122846/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19122846/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19122846/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19122846/transcript.vtt" type="text/vtt" />
    <itunes:duration>1027</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Aligning Upstream And Downstream Development (Part 1)</itunes:title>
    <title>Aligning Upstream And Downstream Development (Part 1)</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedi...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” panelists from the <em>Bioprocess Online Live</em> event “<a href='https://www.bioprocessonline.com/doc/optimizing-process-development-through-upstream-and-downstream-integration-0001'>Optimizing Process Development Through Upstream And Downstream Integration</a>” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” panelists from the <em>Bioprocess Online Live</em> event “<a href='https://www.bioprocessonline.com/doc/optimizing-process-development-through-upstream-and-downstream-integration-0001'>Optimizing Process Development Through Upstream And Downstream Integration</a>” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/19046261-aligning-upstream-and-downstream-development-part-1.mp3" length="22084270" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-19046261</guid>
    <pubDate>Wed, 22 Apr 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19046261/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19046261/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19046261/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/19046261/transcript.vtt" type="text/vtt" />
    <itunes:duration>1810</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.</itunes:title>
    <title>Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models. Keep up with everything biomanufactur...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18970467-reprogramming-t-cells-and-reducing-manufacturing-costs-with-regcell-s-michael-mccullar-ph-d.mp3" length="22257480" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18970467</guid>
    <pubDate>Wed, 08 Apr 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18970467/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18970467/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18970467/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18970467/transcript.vtt" type="text/vtt" />
    <itunes:duration>1832</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Scaling Regenerative Medicine Production With PolarityBio’s Nikolai Sopko, MD, Ph.D.</itunes:title>
    <title>Scaling Regenerative Medicine Production With PolarityBio’s Nikolai Sopko, MD, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autologous regenerative skin therapy for diabetic foot ulcers. The two discuss the challenges of scaling autologous therapy manufacturing, as well as the success PolarityBio has found in doing so through its parallel processing approach. Keep up with everythin...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autologous regenerative skin therapy for diabetic foot ulcers. The two discuss the challenges of scaling autologous therapy manufacturing, as well as the success PolarityBio has found in doing so through its parallel processing approach.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autologous regenerative skin therapy for diabetic foot ulcers. The two discuss the challenges of scaling autologous therapy manufacturing, as well as the success PolarityBio has found in doing so through its parallel processing approach.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18867986-scaling-regenerative-medicine-production-with-polaritybio-s-nikolai-sopko-md-ph-d.mp3" length="23361784" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18867986</guid>
    <pubDate>Wed, 25 Mar 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18867986/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18867986/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18867986/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18867986/transcript.vtt" type="text/vtt" />
    <itunes:duration>1925</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Pursuing Quality While Maintaining Process Control With Richard Moroney, Ph.D.</itunes:title>
    <title>Pursuing Quality While Maintaining Process Control With Richard Moroney, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philosophy is one of continuous process improvement, as he believes there is "no ceiling" on quality control. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.l...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philosophy is one of continuous process improvement, as he believes there is &quot;no ceiling&quot; on quality control.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philosophy is one of continuous process improvement, as he believes there is &quot;no ceiling&quot; on quality control.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18824767-pursuing-quality-while-maintaining-process-control-with-richard-moroney-ph-d.mp3" length="29896432" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18824767</guid>
    <pubDate>Wed, 11 Mar 2026 00:00:00 -0400</pubDate>
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18824767/transcript" type="text/html" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18824767/transcript.json" type="application/json" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18824767/transcript.srt" type="application/x-subrip" />
    <podcast:transcript url="https://www.buzzsprout.com/2518667/18824767/transcript.vtt" type="text/vtt" />
    <itunes:duration>2468</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Unlocking The Therapeutic Power Of Fibroblasts With Pete O’Heeron And Hamid Khoja, Ph.D.</itunes:title>
    <title>Unlocking The Therapeutic Power Of Fibroblasts With Pete O’Heeron And Hamid Khoja, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence o...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18740809-unlocking-the-therapeutic-power-of-fibroblasts-with-pete-o-heeron-and-hamid-khoja-ph-d.mp3" length="32769154" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18740809</guid>
    <pubDate>Wed, 25 Feb 2026 00:00:00 -0500</pubDate>
    <itunes:duration>2704</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Supporting The Bioprocessing Workforce In The AI Era With Sanofi&#39;s Eric Doerr</itunes:title>
    <title>Supporting The Bioprocessing Workforce In The AI Era With Sanofi&#39;s Eric Doerr</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next generation of biomanufacturing workers in North America, comparing incentives and initiatives in both the U.S. and Canada, where Doerr is based. Doerr also shares his thoughts on the need to proactively train workers in using AI to ensure that it serves as...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next generation of biomanufacturing workers in North America, comparing incentives and initiatives in both the U.S. and Canada, where Doerr is based. Doerr also shares his thoughts on the need to proactively train workers in using AI to ensure that it serves as an enabling tool, rather than a disruptive force.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next generation of biomanufacturing workers in North America, comparing incentives and initiatives in both the U.S. and Canada, where Doerr is based. Doerr also shares his thoughts on the need to proactively train workers in using AI to ensure that it serves as an enabling tool, rather than a disruptive force.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18635895-supporting-the-bioprocessing-workforce-in-the-ai-era-with-sanofi-s-eric-doerr.mp3" length="28546084" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18635895</guid>
    <pubDate>Wed, 11 Feb 2026 00:00:00 -0500</pubDate>
    <itunes:duration>2356</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Putting Pressure On CDMOs With Herman Bozenhardt</itunes:title>
    <title>Putting Pressure On CDMOs With Herman Bozenhardt</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory compliance. Bozenhardt outlines his concerns with the current outsourcing environment, noting a rising rate of noncompliance driven by poor facility maintenance and a shortage of reliable workers. He offers advice to sponsor companies working with CDMOs to help ...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory compliance. Bozenhardt outlines his concerns with the current outsourcing environment, noting a rising rate of noncompliance driven by poor facility maintenance and a shortage of reliable workers. He offers advice to sponsor companies working with CDMOs to help ensure their assets don’t fall victim to poor partnerships and operational mismanagement.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory compliance. Bozenhardt outlines his concerns with the current outsourcing environment, noting a rising rate of noncompliance driven by poor facility maintenance and a shortage of reliable workers. He offers advice to sponsor companies working with CDMOs to help ensure their assets don’t fall victim to poor partnerships and operational mismanagement.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18573542-putting-pressure-on-cdmos-with-herman-bozenhardt.mp3" length="40730197" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18573542</guid>
    <pubDate>Wed, 28 Jan 2026 00:00:00 -0500</pubDate>
    <itunes:duration>3367</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>15</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Data Governance And Regulations For AI Use In GMP With Peter Baker</itunes:title>
    <title>Data Governance And Regulations For AI Use In GMP With Peter Baker</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Peter Baker, former FDA investigator and president of Live Oak Quality Assurance. They discuss Annex 22, the EMA’s GMP annex addressing the use of artificial intelligence (AI) in regulated manufacturing, including where it is sufficient and where it is lacking. Baker reflects on his time at the FDA and offers his own advice on AI and technology adoption and validation in GXP. Keep up with everything biomanufacturing at...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Peter Baker, former FDA investigator and president of Live Oak Quality Assurance. They discuss Annex 22, the EMA’s GMP annex addressing the use of artificial intelligence (AI) in regulated manufacturing, including where it is sufficient and where it is lacking. Baker reflects on his time at the FDA and offers his own advice on AI and technology adoption and validation in GXP.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Peter Baker, former FDA investigator and president of Live Oak Quality Assurance. They discuss Annex 22, the EMA’s GMP annex addressing the use of artificial intelligence (AI) in regulated manufacturing, including where it is sufficient and where it is lacking. Baker reflects on his time at the FDA and offers his own advice on AI and technology adoption and validation in GXP.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18500508-data-governance-and-regulations-for-ai-use-in-gmp-with-peter-baker.mp3" length="32676052" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18500508</guid>
    <pubDate>Sat, 17 Jan 2026 11:00:00 -0500</pubDate>
    <itunes:duration>2699</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>14</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>The Editors’ Roundtable: A 2025 Retrospective Of The Life Science Industry</itunes:title>
    <title>The Editors’ Roundtable: A 2025 Retrospective Of The Life Science Industry</title>
    <itunes:summary><![CDATA[In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by fellow chief editors from across the Life Science Connect ecosystem to reflect on the year and share their industry outlooks for 2026. This editorial roundtable features Katie Anderson, chief editor at Pharmaceutical Online; Jeff Buguliskis, Ph.D., deputy chief editor at Outsourced Pharma; Ben Comer, chief editor at Life Science Leader and host of The Business Of Biotech podcast; Ray Dogum, chief editor at Drug...]]></itunes:summary>
    <description><![CDATA[<p>In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by fellow chief editors from across the Life Science Connect ecosystem to reflect on the year and share their industry outlooks for 2026. This editorial roundtable features Katie Anderson, chief editor at <a href='https://www.pharmaceuticalonline.com/'>Pharmaceutical Online</a>; Jeff Buguliskis, Ph.D., deputy chief editor at <a href='https://www.outsourcedpharma.com/'>Outsourced Pharma</a>; Ben Comer, chief editor at <a href='https://www.lifescienceleader.com/'>Life Science Leader</a> and host of <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>The Business Of Biotech</a> podcast; Ray Dogum, chief editor at <a href='https://www.drugdiscoveryonline.com/'>Drug Discovery Online</a>; Erin Harris, chief editor at <a href='https://www.cellandgene.com/'>Cell &amp; Gene</a> and host of <a href='https://www.cellandgene.com/solution/cell-gene-the-podcast'>Cell &amp; Gene: The Podcast</a>; and Anna Rose Welch, chief editor at <a href='https://www.advancingrna.com/'>Advancing RNA</a>.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this special edition of “Better Biopharma,” host Tyler Menichiello is joined by fellow chief editors from across the Life Science Connect ecosystem to reflect on the year and share their industry outlooks for 2026. This editorial roundtable features Katie Anderson, chief editor at <a href='https://www.pharmaceuticalonline.com/'>Pharmaceutical Online</a>; Jeff Buguliskis, Ph.D., deputy chief editor at <a href='https://www.outsourcedpharma.com/'>Outsourced Pharma</a>; Ben Comer, chief editor at <a href='https://www.lifescienceleader.com/'>Life Science Leader</a> and host of <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>The Business Of Biotech</a> podcast; Ray Dogum, chief editor at <a href='https://www.drugdiscoveryonline.com/'>Drug Discovery Online</a>; Erin Harris, chief editor at <a href='https://www.cellandgene.com/'>Cell &amp; Gene</a> and host of <a href='https://www.cellandgene.com/solution/cell-gene-the-podcast'>Cell &amp; Gene: The Podcast</a>; and Anna Rose Welch, chief editor at <a href='https://www.advancingrna.com/'>Advancing RNA</a>.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18407963-the-editors-roundtable-a-2025-retrospective-of-the-life-science-industry.mp3" length="58781267" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18407963</guid>
    <pubDate>Wed, 31 Dec 2025 00:00:00 -0500</pubDate>
    <itunes:duration>4848</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>13</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D.</itunes:title>
    <title>Combining AI With Operations Research To Advance Biomanufacturing With Tinglong Dai, Ph.D., and Tugce Martagan, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to talk about the potential advancements that can be made in biomanufacturing by combining AI with operations research (OR). You can check out their recent paper on the subject, “Synergizing Artificial Intelligence And Operations Research For Advancements ...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to talk about the potential advancements that can be made in biomanufacturing by combining AI with operations research (OR). You can check out their recent paper on the subject, “Synergizing Artificial Intelligence And Operations Research For Advancements In Biomanufacturing,” here: <a href='https://link.springer.com/epdf/10.1007/s10729-025-09725-7?sharing_token=RsWPImKggnLuwsztf7Y1S_e4RwlQNchNByi7wbcMAY7x0AE_Vqj5xOwaldIl63JrPLRzcTIZn-7Iu6LEV-lGtfKrE2ZoADSYlnvcNAipmXCnruKMpDaS19yEPXSw9A0rbab6H57jkCX1EJOGdqO_VeCnwP3qw80LUT-QFcDzr58%3D'>https://link.springer.com/epdf/10.1007/s10729-025-09725-7?sharing_token=RsWPImKggnLuwsztf7Y1S_e4RwlQNchNByi7wbcMAY7x0AE_Vqj5xOwaldIl63JrPLRzcTIZn-7Iu6LEV-lGtfKrE2ZoADSYlnvcNAipmXCnruKMpDaS19yEPXSw9A0rbab6H57jkCX1EJOGdqO_VeCnwP3qw80LUT-QFcDzr58%3D</a> </p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Tinglong Dai, Ph.D., Bernard T. Ferrari Professor of Business at Johns Hopkins University, and Tugce Martagan, Ph.D., associate professor at Northeastern University, to talk about the potential advancements that can be made in biomanufacturing by combining AI with operations research (OR). You can check out their recent paper on the subject, “Synergizing Artificial Intelligence And Operations Research For Advancements In Biomanufacturing,” here: <a href='https://link.springer.com/epdf/10.1007/s10729-025-09725-7?sharing_token=RsWPImKggnLuwsztf7Y1S_e4RwlQNchNByi7wbcMAY7x0AE_Vqj5xOwaldIl63JrPLRzcTIZn-7Iu6LEV-lGtfKrE2ZoADSYlnvcNAipmXCnruKMpDaS19yEPXSw9A0rbab6H57jkCX1EJOGdqO_VeCnwP3qw80LUT-QFcDzr58%3D'>https://link.springer.com/epdf/10.1007/s10729-025-09725-7?sharing_token=RsWPImKggnLuwsztf7Y1S_e4RwlQNchNByi7wbcMAY7x0AE_Vqj5xOwaldIl63JrPLRzcTIZn-7Iu6LEV-lGtfKrE2ZoADSYlnvcNAipmXCnruKMpDaS19yEPXSw9A0rbab6H57jkCX1EJOGdqO_VeCnwP3qw80LUT-QFcDzr58%3D</a> </p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18363506-combining-ai-with-operations-research-to-advance-biomanufacturing-with-tinglong-dai-ph-d-and-tugce-martagan-ph-d.mp3" length="25897233" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18363506</guid>
    <pubDate>Wed, 17 Dec 2025 00:00:00 -0500</pubDate>
    <itunes:duration>2128</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>12</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Building An Oral Vaccine Platform With Vaxart&#39;s Sean Tucker, Ph.D.</itunes:title>
    <title>Building An Oral Vaccine Platform With Vaxart&#39;s Sean Tucker, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines. They discuss Vaxart’s manufacturing process and how it differs from traditional biopharmaceutical production, as well as the regulatory considerations around its oral vaccines. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines. They discuss Vaxart’s manufacturing process and how it differs from traditional biopharmaceutical production, as well as the regulatory considerations around its oral vaccines.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines. They discuss Vaxart’s manufacturing process and how it differs from traditional biopharmaceutical production, as well as the regulatory considerations around its oral vaccines.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18281070-building-an-oral-vaccine-platform-with-vaxart-s-sean-tucker-ph-d.mp3" length="20560604" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18281070</guid>
    <pubDate>Wed, 03 Dec 2025 00:00:00 -0500</pubDate>
    <itunes:duration>1692</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>11</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis&#39;s Patrick Bilbo</itunes:title>
    <title>Lessons In Scaling Regenerative Medicine Manufacturing With Organogenesis&#39;s Patrick Bilbo</title>
    <itunes:summary><![CDATA[In this episode of "Better Biopharma," Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products. They discuss the construction of Organogenesis's new facility in Rhode Island, as well as how the industry has changed in the company's 40-year history. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on L...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products. They discuss the construction of Organogenesis&apos;s new facility in Rhode Island, as well as how the industry has changed in the company&apos;s 40-year history.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products. They discuss the construction of Organogenesis&apos;s new facility in Rhode Island, as well as how the industry has changed in the company&apos;s 40-year history.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18213746-lessons-in-scaling-regenerative-medicine-manufacturing-with-organogenesis-s-patrick-bilbo.mp3" length="31627712" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18213746</guid>
    <pubDate>Tue, 18 Nov 2025 15:00:00 -0500</pubDate>
    <itunes:duration>2612</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>10</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics&#39; Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D.</itunes:title>
    <title>Navigating The Complexity of Conditionally Active Biologics With Bonum Therapeutics&#39; Diane Hollenbaugh, Ph.D., and Neela Patel, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of "Better Biopharma," host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners. Keep up with everything biomanufacturing at Bioprocess Online: https://w...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by Bonum Therapeutics&apos; chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by Bonum Therapeutics&apos; chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D. They talk about the inherent challenges of developing complex molecules like conditionally active biologics, sharing advice on CMC strategy, analytical methodology, and working with contract manufacturing and development partners.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18112408-navigating-the-complexity-of-conditionally-active-biologics-with-bonum-therapeutics-diane-hollenbaugh-ph-d-and-neela-patel-ph-d.mp3" length="34729489" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18112408</guid>
    <pubDate>Wed, 05 Nov 2025 00:00:00 -0500</pubDate>
    <itunes:duration>2869</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>9</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Developing Antibodies To Block Neuroinflammation With MindImmune&#39;s Stevin Zorn, Ph.D.</itunes:title>
    <title>Developing Antibodies To Block Neuroinflammation With MindImmune&#39;s Stevin Zorn, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.l...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by MindImmune&apos;s president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company&apos;s lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer&apos;s disease.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by MindImmune&apos;s president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company&apos;s lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer&apos;s disease.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/18043495-developing-antibodies-to-block-neuroinflammation-with-mindimmune-s-stevin-zorn-ph-d.mp3" length="32055172" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-18043495</guid>
    <pubDate>Wed, 22 Oct 2025 00:00:00 -0400</pubDate>
    <itunes:duration>2668</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>8</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.</itunes:title>
    <title>Engineering Bacterial Vector-Based Immunotherapies With OS Therapies’ Paul Romness and Robert Petit, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Fol...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma. They also explain the unique CMC challenges around developing a safe bacterial vector.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17970230-engineering-bacterial-vector-based-immunotherapies-with-os-therapies-paul-romness-and-robert-petit-ph-d.mp3" length="26691026" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17970230</guid>
    <pubDate>Wed, 08 Oct 2025 00:00:00 -0400</pubDate>
    <itunes:duration>2198</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>7</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>How J&amp;J Is Tackling Alzheimer&#39;s Disease With Fiona Elwood, Ph.D.</itunes:title>
    <title>How J&amp;J Is Tackling Alzheimer&#39;s Disease With Fiona Elwood, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson &amp; Johnson. The two talk about J&amp;J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson &amp; Johnson. The two talk about J&amp;J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Fiona Elwood, Ph.D., VP and Neurodegeneration Disease Area Stronghold Leader at Johnson &amp; Johnson. The two talk about J&amp;J’s end-to-end organizational structure and its modality-agnostic approach to treating Alzheimer’s disease.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17888975-how-j-j-is-tackling-alzheimer-s-disease-with-fiona-elwood-ph-d.mp3" length="23927330" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17888975</guid>
    <pubDate>Wed, 24 Sep 2025 00:00:00 -0400</pubDate>
    <itunes:duration>1970</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>6</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>CDMO Hunger Games And The State Of Biotech With Siren Biotechnology&#39;s Nicole Paulk, Ph.D.</itunes:title>
    <title>CDMO Hunger Games And The State Of Biotech With Siren Biotechnology&#39;s Nicole Paulk, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined ...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined which CDMO won Siren’s business.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nicole Paulk, Ph.D., CEO and founder of Siren Biotechnology, a company developing a universal AAV immuno-gene therapy for cancer. They discuss the company’s decision to switch from plasmids to producer cell lines (PCLs) in production, the current funding environment for cell and gene therapies (CGTs), how companies are innovating and doing more with less, and the unconventional head-to-head competition that determined which CDMO won Siren’s business.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17817081-cdmo-hunger-games-and-the-state-of-biotech-with-siren-biotechnology-s-nicole-paulk-ph-d.mp3" length="44022276" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17817081</guid>
    <pubDate>Wed, 10 Sep 2025 00:00:00 -0400</pubDate>
    <itunes:duration>3640</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>5</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Delivering Biologics To The Brain With Adaptin Bio&#39;s Michael Roberts, Ph.D., and Duke University&#39;s Mustafa Khasraw, MD</itunes:title>
    <title>Delivering Biologics To The Brain With Adaptin Bio&#39;s Michael Roberts, Ph.D., and Duke University&#39;s Mustafa Khasraw, MD</title>
    <itunes:summary><![CDATA[In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD. They discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and the development and manufacturing challenges behind the company's lead asset, APTN-101.  Keep up with everything biomanufacturing at Bioproce...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by Adaptin Bio&apos;s CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University&apos;s Mustafa Khasraw, MD. They discuss Adaptin&apos;s Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and the development and manufacturing challenges behind the company&apos;s lead asset, APTN-101. </p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of &quot;Better Biopharma,&quot; host Tyler Menichiello is joined by Adaptin Bio&apos;s CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University&apos;s Mustafa Khasraw, MD. They discuss Adaptin&apos;s Brain Bispecific T-cell Engager (BRiTE) platform, its clinical potential to deliver therapeutic T cells across the blood-brain barrier, and the development and manufacturing challenges behind the company&apos;s lead asset, APTN-101. </p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17731684-delivering-biologics-to-the-brain-with-adaptin-bio-s-michael-roberts-ph-d-and-duke-university-s-mustafa-khasraw-md.mp3" length="26365953" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17731684</guid>
    <pubDate>Wed, 27 Aug 2025 00:00:00 -0400</pubDate>
    <itunes:duration>2171</itunes:duration>
    <itunes:keywords>biotech, betterbiopharma, biomanufacturing, biologics, bloodbrainbarrier, drugdevelopment, cancer</itunes:keywords>
    <itunes:episode>4</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Developing An In Vivo CAR-T With Interius BioTherapeutics&#39; Sianny Christanti and Babu Medi, Ph.D.</itunes:title>
    <title>Developing An In Vivo CAR-T With Interius BioTherapeutics&#39; Sianny Christanti and Babu Medi, Ph.D.</title>
    <itunes:summary><![CDATA[On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Fo...]]></itunes:summary>
    <description><![CDATA[<p>On this episode of <em>Better Biopharma</em>, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector&apos;s design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>On this episode of <em>Better Biopharma</em>, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector&apos;s design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17654399-developing-an-in-vivo-car-t-with-interius-biotherapeutics-sianny-christanti-and-babu-medi-ph-d.mp3" length="35326153" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17654399</guid>
    <pubDate>Wed, 13 Aug 2025 00:00:00 -0400</pubDate>
    <itunes:duration>2919</itunes:duration>
    <itunes:keywords>biotech, better biopharma, biomanufacturing, biologics, CAR-T, pharma</itunes:keywords>
    <itunes:episode>3</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Functional Antibody Screening With Abalone Bio&#39;s Richard Yu, Ph.D.</itunes:title>
    <title>Functional Antibody Screening With Abalone Bio&#39;s Richard Yu, Ph.D.</title>
    <itunes:summary><![CDATA[In this episode of Better Biopharma, Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains how the company's functional antibody selection technology (FAST) platform differs from traditional affinity screening. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/ Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions Tell us how we...]]></itunes:summary>
    <description><![CDATA[<p>In this episode of <em>Better Biopharma</em>, Abalone Bio&apos;s CEO and co-founder, Richard Yu, Ph.D., explains how the company&apos;s functional antibody selection technology (FAST) platform differs from traditional affinity screening.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>In this episode of <em>Better Biopharma</em>, Abalone Bio&apos;s CEO and co-founder, Richard Yu, Ph.D., explains how the company&apos;s functional antibody selection technology (FAST) platform differs from traditional affinity screening.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17576058-functional-antibody-screening-with-abalone-bio-s-richard-yu-ph-d.mp3" length="31771066" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17576058</guid>
    <pubDate>Wed, 30 Jul 2025 00:00:00 -0400</pubDate>
    <itunes:duration>2625</itunes:duration>
    <itunes:keywords></itunes:keywords>
    <itunes:episode>2</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>Using Algae To Manufacture Oral Biologics With Lumen Bioscience&#39;s Craig Behnke, Ph.D.</itunes:title>
    <title>Using Algae To Manufacture Oral Biologics With Lumen Bioscience&#39;s Craig Behnke, Ph.D.</title>
    <itunes:summary><![CDATA[Lumen Bioscience is putting the farm in biopharma — literally! In this episode of Better Biopharma, Lumen's EVP of production and development, Craig Behnke, Ph.D., explains the company's chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria. Check out Behnke's past appearance on Business Of Biotech: https: //www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002 Keep up with everything biomanufacturing a...]]></itunes:summary>
    <description><![CDATA[<p>Lumen Bioscience is putting the farm in biopharma — literally! In this episode of <em>Better Biopharma</em>, Lumen&apos;s EVP of production and development, Craig Behnke, Ph.D., explains the company&apos;s chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria.</p><p>Check out Behnke&apos;s past appearance on <em>Business Of Biotech</em>: https: <a href='https://www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002'>//www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002</a></p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>Lumen Bioscience is putting the farm in biopharma — literally! In this episode of <em>Better Biopharma</em>, Lumen&apos;s EVP of production and development, Craig Behnke, Ph.D., explains the company&apos;s chlorophyll-powered approach to bioprocessing using photosynthetic cyanobacteria.</p><p>Check out Behnke&apos;s past appearance on <em>Business Of Biotech</em>: https: <a href='https://www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002'>//www.lifescienceleader.com/doc/democratizing-biologics-with-lumen-bioscience-s-brian-finrow-j-d-craig-behnke-ph-d-0002</a></p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17510402-using-algae-to-manufacture-oral-biologics-with-lumen-bioscience-s-craig-behnke-ph-d.mp3" length="32357374" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17510402</guid>
    <pubDate>Wed, 16 Jul 2025 06:00:00 -0400</pubDate>
    <itunes:duration>2674</itunes:duration>
    <itunes:keywords>better biopharma, biologics, bioprocessing, manufacturing, biotech</itunes:keywords>
    <itunes:episode>1</itunes:episode>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
  <item>
    <itunes:title>PILOT: Introducing Better Biopharma</itunes:title>
    <title>PILOT: Introducing Better Biopharma</title>
    <itunes:summary><![CDATA[How can the biopharmaceutical industry improve? Join Bioprocess Online's Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they're moving the needle to make better medicines and optimize manufacturing. Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/ Follow Tyler Menichiello o...]]></itunes:summary>
    <description><![CDATA[<p>How can the biopharmaceutical industry improve? Join Bioprocess Online&apos;s Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they&apos;re moving the needle to make better medicines and optimize manufacturing.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></description>
    <content:encoded><![CDATA[<p>How can the biopharmaceutical industry improve? Join Bioprocess Online&apos;s Tyler Menichiello as he explores this question through a series of interviews with experts and leaders from across the space. Subscribe for biweekly, in-depth conversations with the brightest minds in biotech to learn how they&apos;re moving the needle to make better medicines and optimize manufacturing.</p><p>Keep up with everything biomanufacturing at <em>Bioprocess Online:</em> <a href='https://www.bioprocessonline.com/'>https://www.bioprocessonline.com/</a></p><p>Follow Tyler Menichiello on LinkedIn: <a href='https://www.linkedin.com/in/tmenichiello/'>https://www.linkedin.com/in/tmenichiello/</a></p><p>Subscribe to our newsletters: <a href='https://www.bioprocessonline.com/user/edit/subscriptions'>https://www.bioprocessonline.com/user/edit/subscriptions</a></p><p>Tell us how we can improve. Take our 60-second survey: <a href='https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header'>https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header</a></p>]]></content:encoded>
    <enclosure url="https://www.buzzsprout.com/2518667/episodes/17509828-pilot-introducing-better-biopharma.mp3" length="2145126" type="audio/mpeg" />
    <itunes:author>Tyler Menichiello</itunes:author>
    <guid isPermaLink="false">Buzzsprout-17509828</guid>
    <pubDate>Wed, 16 Jul 2025 06:00:00 -0400</pubDate>
    <itunes:duration>165</itunes:duration>
    <itunes:keywords>biotech, better biopharma, biomanufacturing, biologics</itunes:keywords>
    <itunes:episodeType>full</itunes:episodeType>
    <itunes:explicit>false</itunes:explicit>
  </item>
</channel>
</rss>
